Can Combination Therapy with Endothelin Receptor Antagonist and PDE5 Inhibitors Prevent Echocardiographic Findings Suspicious for Pulmonary Arterial Hypertension? Description of a Real-Life Case Series

Objective: To retrospectively evaluate the incidence rate (IR) of elevated echocardiographic estimated systolic pulmonary artery pressure (sPAP), suspected for pulmonary hypertension (PH), in systemic sclerosis (SSc) patients after the introduction of a combination therapy with bosentan and sildenaf...

Повний опис

Бібліографічні деталі

Автори:	Arianna Damiani, Gemma Lepri, Francesco Bonomi, Elisa Fiorentini, Silvia Peretti, Jelena Blagojevic, Silvia Bellando Randone, Serena Guiducci
Формат:	Artigo
Мова:	Inglês
Опубліковано:	MDPI AG 2024-07-01
Серія:	Diagnostics
Предмети:	systemic sclerosis pulmonary hypertension phosphodiesterase-5 inhibitors endothelin receptor antagonist
Онлайн доступ:	https://www.mdpi.com/2075-4418/14/14/1526
Теги:	Додати тег Немає тегів, Будьте першим, хто поставить тег для цього запису!